AGW-11
AGW-11 is a potent dual inhibitor of EGFR (IC50 = 556 nM) and VEGFR2 (IC50 = 289.7 nM). AGW-11 induces apoptosis and suppresses phosphorylation of EGFR, VEGFR2, and ERK1/2 in HUVECs. AGW-11 effectively inhibits cancer cell growth, reduces HUVEC proliferation, tube formation, and invasion, thereby blocking angiogenesis. AGW-11 significantly suppresses tumor growth and decreases lung metastasis in a 4T1 xenograft mouse model. AGW-11 can be used for the study of breast cancer.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Fòrmula: C31H36N2O6
- Peso molecular:532.63
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Ver todos los productos específicos de isoformas VEGFR
MoreVer todos los productos específicos de isoformas EGFR
More
Actividad biológica
|
VEGFR2 289.7 nM (IC50) |
EGFR 556 nM (IC50) |
AGW-11 (0.5-30 μM, 48 h) exhibits potent antiproliferative activity against MDA-MB-231, 4T1, A2780, and HCT-116 cancer cells, with IC50 values of 1.26 μM, 2.85 μM, 0.75 μM, and 1.58 μM, respectively[1].
AGW-11 (0.5-2 μM, 24 h) significantly inhibits the phosphorylation of EGFR and ERK1/2 in MDA-MB-231 cells in a concentration-dependent manner[1].
AGW-11 (2 μM, 24 h) potently inhibits colony formation and induces apoptosis in 4T1 breast cancer cells[1].
AGW-11 (1-4 μM, 6-24 h) potently suppresses tube formation of HUVECs and exerts concentration-dependent inhibitory activity on HUVEC invasion[1].
AGW-11 (1-4 μM, 24 h) effectively reduces the phosphorylation of VEGFR2 and ERK1/2 in n HUVECs in a concentration-dependent manner[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB-231 cells
-
Concentration:0.5, 1. 2 μM
-
Incubation Time:24 h
-
Result:Inhibited the phosphorylation of EGFR and ERK1/2 in MDA-MB-231 cells in a concentration-dependent manner.
-
Cell Line:4T1 breast cancer cells
-
Concentration:2 μM
-
Incubation Time:24 h
-
Result:Induced apoptosis in 4T1 breast cancer cells.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:4T1 mouse breast cancer cells (1×106 cells per mouse) were subcutaneously inoculated into the dorsal region of 4-6-week-old female BALB/c mice (18-20 g body weight)[1]
-
Dosage:1 mg/kg and 5 mg/kg
-
Administration:i.p., once every 2 days, 20 days
-
Result:Achieved tumor volume reduction rates of 34.5% and 32.4% at doses of 1 mg/kg and 5 mg/kg.
Showed no significant changes in body weight.
Reduced the Ki67 expression and reduced the CD31 and VEGF expressions.
Decreased the phosphorylation of VEGFR2 and its downstream molecule ERK1/2.
Increased the level of cleaved caspase 3.
Reduced the number of metastatic lung nodules.
Enhanced tumor necrosis and inhibited abnormal transformation of liver and lung tissues.
Chemical Information
-
Peso molecular 532.63
-
Fòrmula C31H36N2O6
-
SMILES
CC(OC[C@]([C@]1([H])[C@@]([C@H](C/C=C2C(OC[C@@H]/2OC3=C4N=CC=CC4=CC=C3)=O)C(CC1)=C)(C)CC5)(C)NC5=O)=O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)